XL092 (Exelixis)
Description: A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors
Mechanism of Action: Tyrosine Kinase Inhibitor targeting VEGFR2, MET, AXL, TAM (AXL and MER).
Target Patient Population: Study currently has slots for monotherapy in clear cell RCC and combination therapy (with Avelumab or Atezolizumab) in advanced solid tumors.
Study Design: Study drug is given orally daily.